Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Thursday, May 9th.

Can-Fite BioPharma Price Performance

Shares of NYSE CANF opened at $2.42 on Wednesday. The firm has a fifty day moving average price of $2.47 and a 200-day moving average price of $2.23. The stock has a market cap of $8.57 million, a PE ratio of -1.35 and a beta of 1.45. Can-Fite BioPharma has a 1 year low of $1.81 and a 1 year high of $4.48.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC acquired a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned approximately 0.57% of Can-Fite BioPharma at the end of the most recent reporting period. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.